Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Orion Market Research | PRODUCT CODE: 1123231

Cover Image

PUBLISHER: Orion Market Research | PRODUCT CODE: 1123231

Global Postmenopausal Osteoporosis Market Research and Forecast 2022-2028

PUBLISHED:
PAGES: 105 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4000
Printable PDF & Excel (Corporate License)
USD 6625

Add to Cart

Global Postmenopausal Osteoporosis Market Size, Share & Trends Analysis Report by Treatment (Bisphosphonates, Hormones, Strontium Ranelate, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce Pharmacies) Forecast 2021-2027

The global postmenopausal osteoporosis market is anticipated to grow at a CAGR of around 3.6% during the forecast period. Osteoporosis is a form of disorder caused by skeletal fragility, low bone mass, and microarchitectural. It results in a condition where bone mass and bone density decrease that may increase the chances of bone fracture in long run. The factors contributing to the growth of the market include the growing prevalence of osteoporosis and improvement in healthcare infrastructure in emerging economies. Additionally, changing lifestyles where people are addicted to smoking and alcohol and increasing awareness among people regarding the disorder and advancement in drugs and approval by the FDA is also driving the growth of the market. Moreover, the higher standards approval regulation process of products, rising generic competition, and patent expiration will be hampering the growth of the market. Moreover, new application developments and innovation in product designs and geographic expansions by various market players are creating an opportunity for market growth.

Segmental Outlook

The global postmenopausal osteoporosis market is segmented based on the treatment and distribution channel. Based on treatment, the market is segmented into bisphosphonates, hormones, strontium ranelate, and others. Further on the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, e-commerce pharmacies.

Global Postmenopausal Osteoporosis Market Share by Treatment, 2020 (%)

Global Postmenopausal Osteoporosis Market Share by Treatment

The bisphosphonates segment is projected to have a significant share in the global Postmenopausal Osteoporosis Market

Among treatment, the bisphosphonates segment projected to have a considerable share in the market. These are a group of drugs that treats slowing bone loss. It also reduces the risk of hip and spine fractures in osteoporosis. These are used at different doses that support in treating Paget's disease of bone. Bisphosphonates are usually well tolerated by patients and the risk of digestive problems with oral preparations is reduced while taken carefully following the instructions. It has very few side effects including, a sore mouth, muscle pain, headaches, flu, bone pain, and others. People with severe kidney problems, pregnant women, people who are taking parathyroid hormone currently, and people with esophagitis cannot take bisphosphonates. Different types of bisphosphonates include ibandronic acid, zoledronic acid, sodium clodronate, and disodium pamidronate. The various advantages of bisphosphonates include it prevents bone loss, improves bone strength and preserves the bone structure, and reduces the fracture risks in patients with osteoporosis.

Regional Outlooks

The global postmenopausal osteoporosis market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is projected to dominate the market during the forecast period of 2021 followed by Europe attributed to factors such as early adoption rates of treatments, growing aged population who more have chances of the osteoporosis disease. Whereas Europe has been considered as the second largest region attributing to factors such as high diagnostic rates and better healthcare infrastructure in the region.

Global Postmenopausal Osteoporosis Market Growth, by Region 2021-2027

Global Postmenopausal Osteoporosis Market Growth, by Region

Asia-Pacific will have considerable growth in the global postmenopausal osteoporosis market

Asia-Pacific is projected to grow at a significant CAGR in the postmenopausal osteoporosis market during the forecast period. The growth is attributed to increasing healthcare spending and improvement in healthcare infrastructure in the region. The simultaneous development in the medical tourism industry in the following industry also propelling the market growth. Major players including Eily Lily and Co, Pfizer Inc, Protector& Gamble are also having their operation in the region and contributing significantly to the growth of the market.

Market Players Outlook

The key players of the postmenopausal osteoporosis market include Eli Lilly and CO., Pfizer Inc., Proctor & Gamble Co., Amgen Inc., Novartis International AG, Allergan plc, and others. The market players are considerably contributing to the market growth by adopting various strategies including mergers, and acquisitions, collaborations, and new product launches. For instance, in December 2018, GlaxoSmithKline plc and TESARO Inc announced that GSK will be acquiring TESARO that is an oncology-focused company. This acquisition will be strengthening GSK pharmaceutical business along with accelerating the GSK pipeline and its commercial capability in the oncology business.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Postmenopausal Osteoporosis market.

Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Product Code: OMR2018364

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Postmenopausal Osteoporosis Industry
  • Recovery Scenario of Global Postmenopausal Osteoporosis Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key strategy Analysis
  • 3.3. Impact of COVID-19 on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Postmenopausal Osteoporosis market by Treatment
    • 5.1.1. Bisphosphonates
    • 5.1.2. Hormones
    • 5.1.3. Strontium Ranelate
    • 5.1.4. Others (Rank Ligand Inhibitors)
  • 5.2. Global Postmenopausal Osteoporosis market by Distribution Channel
    • 5.2.1. Hospital Pharmacies
    • 5.2.2. Retail Pharmacies
    • 5.2.3. E- Commerce Pharmacies

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Allergan Plc
  • 7.2. Amgen Inc.
  • 7.3. Biologicsmd, Inc.
  • 7.4. Eli Lilly And Co.
  • 7.5. F. Hoffmann-La Roche Ltd.
  • 7.6. Glaxosmithkline Plc
  • 7.7. Ligand Pharmaceuticals, Inc.
  • 7.8. Merck & Co., Inc.
  • 7.9. Novartis International AG
  • 7.10. Novo Nordisk Inc.
  • 7.11. Outlook Therapeutics, Inc.
  • 7.12. Paras Biopharmaceuticals Finland Oy
  • 7.13. Pfizer Inc.
  • 7.14. Phytohealth Corp.
  • 7.15. Procter & Gamble Co.
  • 7.16. Radius Health Inc.
  • 7.17. Sanofi S.A.
  • 7.18. Tarsa Therapeutics, Inc.
  • 7.19. Teva Pharmaceuticals Industries Ltd.
Product Code: OMR2018364

LIST OF TABLES

  • 1. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
  • 2. GLOBAL BISPHOSPHONATES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 3. GLOBAL HORMONES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL STRONTIUM RANELATE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

5. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL,

  • 6. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS FOR HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027($ MILLION)
  • 7. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS FOR RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 8. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS FORE-COMMERCE PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 10. NORTH AMERICAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 11. NORTH AMERICAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
  • 12. NORTH AMERICAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL,2020-2027 ($ MILLION)
  • 13. EUROPEAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 14. EUROPEAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
  • 15. EUROPEAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 16. ASIA-PACIFIC POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 17. ASIA-PACIFIC POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
  • 18. ASIA-PACIFIC POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 19. REST OF THE WORLD POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 20. REST OF THE WORLD POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
  • 21. REST OF THE WORLD POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, 2020-2027 (%)
  • 4. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET SHARE BY TREATMENT,2020 VS 2027 (%)
  • 5. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET SHARE BY DISTRIBUTION CHANNEL, 2020 VS 2027 (%)
  • 6. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET SHARE BY MATERIAL, 2020 VS 2027 (%)
  • 7. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL BISPHOSPHONATES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL HORMONES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL STRONTIUM RANELATE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL HOSPITAL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. GLOBAL RETAIL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. GLOBAL E- COMMERCE PHARMACIES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 14. US POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 15. CANADA POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 16. UK POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 17. FRANCE POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 18. GERMANY POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 19. ITALY POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 20. SPAIN POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 21. REST OF EUROPE POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 22. INDIA POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 23. CHINA POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 24. JAPAN POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 25. SOUTH KOREA POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 26. REST OF ASIA-PACIFIC POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 27. REST OF THE WORLD POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!